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Abstract
There have been many reports published in recent years on atypical subtrochanteric fractures after long-term bisphosphonates therapy. In
a description of a few series of cases, fractures of typical clinical course and radiological image have been documented. These fractures are
estimated as very rare (2.3 per 10,000 patient-years). It is suggested that a subsequent use of steroids or proton pump inhibitors with
bisphosphonates may increase the risk of fracture occurrence. (Pol J Endocrinol 2011; 62 (1): 84–87)
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Streszczenie
W ostatnich latach ukazało się wiele publikacji dotyczących atypowych złamań podkrętarzowych po długotrwałym leczeniu bisfosfonia-
nami. W opisie kilku serii przypadków udokumentowano wystąpienie złamań o typowym przebiegu klinicznym i obrazie radiologicz-
nym. Doniesienia te nie zostały potwierdzone w badaniach epidemiologicznych, które jednak nie mają znamienności statystycznej. Oce-
nia się, że złamania te są bardzo rzadkie (2,3 na 10 000 lat życia pacjentów). Sugeruje się, że równoczesne stosowanie steroidów lub
inhibitorów pompy protonowej z bisfosfonianami może zwiększać ryzyko wystąpienia złamania.
(Endokrynol Pol 2011; 62 (1): 84–87)
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Introduction
Osteoporosis is a chronic disease requiring long-term
treatment. At present, bisphosphonates dominate ther-
apy, with alendronate being the most commonly pre-
scribed medical agent, followed by ibandronate, risedr-
onate and, more rarely, zoledronate. Clinical studies last-
ing 3–5 years have demonstrated both their safety and
high degree of efficacy in preventing osteoporotic frac-
tures (at approximately 50%) [1–3]. The question arises
if their use over a much longer period, perhaps 10 years,
is also safe.
A recently raised question is the possibility of fatigue
subtrochanteric fracture occurrence, the fracture re-
ferred to in the literature as ‘atypical’. Subtrochanteric
fractures (to 5 cm below the smaller trochanter) are the
rarest form of the proximal end of the femoral bone. In
Poland, they constitute 5.6% of the femoral bone frac-
tures in its proximal end with 50.4% being femoral neck
fractures and 44% intertrochanteric fractures [4].
Bone microcracks and fatigue fracture
The therapeutic effect of bisphosphonates in osteoporosis
results from their antiresorptive activity. Bisphospho-
nates reduce the number of newly formed osteoclasts,
and decrease their activity while enhancing their apop-
tosis. In this way, they prevent further bone destruction
and, by considerably slowing down its restructuring
rate, they induce secondary mineralisation, increasing
bone density [1]. Continuous bone remodelling is nec-
essary to maintain its quality in the anti-fracture resis-
tance context. The remodelling process always starts
from bone resorption, initiated by the occurrence of mi-
crocracks. The resorption stage may proceed to bone
formation process. Strong and long-term inhibition of
bone resorption disables its remodelling, thus increas-
ing the remineralisation process, which increases bone
rigidity and causes an accumulation of microcracks. The
accumulation of microcracks leads to microfractures and
may bring about a fatigue fracture.
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Such fractures have been seen in subjects with os-
teoporosis treated with high fluoride doses, which
caused excessive bone mineralisation [5]. Fatigue frac-
tures also occur where bone remodelling does not fol-
low excessive mechanical loads being put on the skele-
ton. These include well-known metatarsal bone frac-
tures in army recruits or subtrochanteric fractures in
unadapted runners after long training [6, 7].
Microcracks are rarely described in bone biopsy spec-
imen from patients treated for osteoporosis. This is be-
cause, first of all, special staining techniques of bone spec-
imen are necessary to visualise microcracks and such
techniques are applied only in exceptional situations.
A certain enhancement of microcracks after large doses
of bisphosphonates was documented in experimental
studies on dogs [8]. Stepan et al. found an increased num-
ber of microcracks in women treated with bisphospho-
nates over a long period as compared to control group [9].
Atypical subtrochanteric fractures:
a series of cases
In 2005, one of the first reports was published on fa-
tigue subtrochanteric fractures after long-term therapy
with bisphosphonates. Odvina et al. described nine cas-
es of atypical subtrochanteric fractures in female patients
treated with bisphosphonates for a period of 1–8 years.
Some of those patients had received steroids and oestro-
gen agents. Delayed fracture healing was noted in four
of them [10]. Since then, several dozen reports have been
published, describing the characteristic clinical course
of the disease and corresponding radiological images.
In 2008, Kwek et al. [11], having analysed all the ad-
missions of patients with low-energy fractures over a pe-
riod of two years, identified 17 cases of subtrochanteric
fractures. All the patients had been receiving bisphospho-
nates for 4.4 years on average (range 2–8 years). None of
the patients had received any additional bone metabo-
lism-affecting agent. In most patients, subtrochanteric frac-
tures were preceded by pain, lasting from one week to
two years. Thickened cortical bone layer dominated in
radiological images, followed by transverse fracture. In
three patients, a new fracture occurred on the other side
a few months after the first fracture (Figures 1–3) [11].
In 2009,  Lenart et al.  [12] compared low-energy
subtrochanteric fractures to femoral neck and intertro-
chanteric fractures among patients admitted over a pe-
riod of seven years. This included 41 subtrochanteric
fractures and 82 femoral neck and intertrochanteric frac-
tures. Out of 15 patients with subtrochanteric fractures,
ten had been receiving bisphosphonates for 7.3 years
on average. In radiological images, thickened cortical
bone layer was observed, with its internal prominence.
Performed studies have demonstrated significantly
longer duration of bisphosphonate therapy in subjects
with atypical fractures vs. those with intertrochanteric
or femoral neck fractures [12].
Atypical subtrochanteric fractures:
epidemiological data
Atypical subtrochanteric fractures constitute 5–10% of
fractures of the proximal femoral bone [4, 13, 14]. The
described series of atypical fracture cases do not find
support in epidemiological data, mainly due to the rar-
ity of subtrochanteric fractures in all circumstances.
In 2010, Black et al. [15] evaluated proximal femoral
bone fractures in large clinical studies: the FIT study of
alendronate, the FLEX study, where theFIT study was
extended by a further 10 years, and the HORIZON
study on zoledronate. All the proximal femoral bone
fractures were analysed and the material comprised
14,195 women of post-menopausal age, in whom only
284 fractures of the proximal femoral bone were found.
Just 12 subtrochanteric fractures were identified in
ten patients. Unfortunately, the authors had only one
radiogram to view (sic!) and possible examples of atypi-
cal fractures were described only on the basis of radio-
logical reports. The risk of subtrochanteric fracture was
estimated at the incidence level of 2.3 per 10,000,000 pa-
tient-years. In particular studies with placebo, the rela-
tive risk of its occurrence vs. the control group was:
1.03 for alendronate (FIT 95% CI, 0.06–16.46), 1.5 for
zoledronate (HORIZON-PFT 95% CI, 0.25–9.00), and 1.33
for prolonged alendronate (FLEX 95% CI, 0.12 to 14.67).
The results did not have statistical significance. The large
dispersion of results was the consequence of a small num-
ber of cases. It should be stated, however, that no subtro-
chanteric fractures were found in the FLEX study after
the ten-year administration of alendronate [15].
We would like to draw attention to the fact that frac-
tures can be influenced by additional factors, such as the
use of steroids [16, 17] and proton pump inhibitors [18,19].
Summary
It appears from the available reports that fatigue frac-
tures may occur in bisphosphonate-treated patients, and
such fractures are also seen in cases unrelated to os-
teoporosis therapy. In the series of described cases of
atypical subtrochanteric fractures, their characteristic
radiological picture was presented, which was identi-
cal in the reports of several different authors. Epidemi-
ological data does not unequivocally confirm the in-
creased risk of the occurrence of these fractures in the
course of bisphosphonate use, but neither does it ex-
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clude such a possibility. It is known, however, that these
fractures are extremely rare (2.3 per 10,000,000 patient-
years). Most probably, the risk for their occurrence may
result from the concomitant use of steroids or proton
pump inhibitors. All agree that this problem requires
further study.
Figure 1. Radiogram of a female patient shows the characteristic picture of atypical subtrochanteric fracture. Cortical thickening with
medial spike and transverse, short, oblique fracture [11], by courtesy of Prof. Ernest Kwek
Rycina 1. Radiogram chorej dokumentuje charakterystyczny obraz atypowego złamania podkrętarzowego. Pogrubienie warstwy korowej
z uwypukleniem wewnętrznym oraz poprzeczne, skośne złamanie [11], dzięki uprzejmości Prof. Ernesta Kweka
Figure 3. Bone scintigraphy of a patient presented on Figure 2.
Status after subtrochanteric fracture fixation on the left, and
increased uptake of marker on the right side
Rycina 3. Scyntygrafia chorej z ryciny 2. Stan po zespoleniu
złamania podkrętarzowego po stronie lewej. Widoczne zwiększenie
wychwytu znacznika po stronie prawej [11], dzięki uprzejmości
Prof. Ernesta Kweka
Figure 2. A female patient, 55 years old, treated with alendronate
for 5 years. On the right side, typical, short oblique fracture, and
on the left side, cortical thickening are visible. [11], by courtesy of
Prof. Ernest Kwek
Rycina 2. Chora 55 lat, leczona 5 lat alendronianem. Po prawej
typowe złamanie krótkie skośne a po lewej pogrubienie warstwy
korowej [11], dzięki uprzejmości Prof. Ernesta Kweka
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